Linaclotide

Drug Profile

Linaclotide

Alternative Names: ASP-0456; ASP-456; Constella; Linaclotide acetate; Linzess; MD-1100; MM-416775

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Microbia
  • Developer Allergan; Astellas Pharma; AstraZeneca; Ironwood Pharmaceuticals
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Oligopeptides
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Constipation; Irritable bowel syndrome

Highest Development Phases

  • Marketed Constipation; Irritable bowel syndrome

Most Recent Events

  • 09 Mar 2017 Ironwood plans a phase III trial of linaclotide colonic release-1 formulation in Irritable bowel syndrome (In adults)
  • 29 Jan 2017 Efficacy and adverse event data from a phase III trial in Constipation was released by Astellas Pharma and and Ironwood Pharmaceuticals
  • 26 Jan 2017 The USFDA approves 72µg dose of linaclotide for Constipation in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top